Suzanne C. Li

Dr. Suzanne C. Li


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2020 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
AJAdriana A. de Jesus
Adriana A. de Jesus
YHYangfeng Hou
Yangfeng Hou
SBStephen Brooks
Stephen Brooks
LMLouise Malle
Louise Malle
ABAngelique Biancotto
Angelique Biancotto
RGRaphaela Goldbach-Mansky
Raphaela Goldbach-Mansky
BACKGROUND. Undifferentiated systemic autoinflammatory diseases (USAIDs) present diagnostic and therapeutic challenges. Chronic interferon (IFN) signaling and cytokine dysregulation may identify diseases with available targeted treatments. METHODS. Sixty-six consecutively referred USAID patients underwent underwent screening for the presence of an interferon signature using a standardized type-I IFN-response-gene score (IRG-S), cytokine profiling, and genetic evaluation by next-generation sequencing. RESULTS. Thirty-six USAID patients (55%) had elevated IRG-S. Neutrophilic panniculitis (40% vs. 0%), basal ganglia calcifications (46% vs. 0%), interstitial lung disease (47% vs. 5%), and myositis (60% vs. 10%) were more prevalent in patients with elevated IRG-S. Moderate IRG-S elevation and highly elevated serum IL-18 distinguished 8 patients with pulmonary alveolar proteinosis (PAP) and recurrent macrophage activation syndrome (MAS). Among patients with panniculitis and progressive cytopenias, 2 patients were compound heterozygous for potentially novel LRBA mutations, 4 patients harbored potentially novel splice variants in IKBKG (which encodes NF-κB essential modulator [NEMO]), and 6 patients had de novo frameshift mutations in SAMD9L. Of additional 12 patients with elevated IRG-S and CANDLE-, SAVI- or Aicardi-Goutières syndrome–like (AGS-like) phenotypes, 5 patients carried mutations in either SAMHD1, TREX1, PSMB8, or PSMG2. Two patients had anti-MDA5 autoantibody–positive juvenile dermatomyositis, and 7 could not be classified. Patients with LRBA, IKBKG, and SAMD9L mutations showed a pattern of IRG elevation that suggests prominent NF-κB activation different from the canonical interferonopathies CANDLE, SAVI, and AGS. CONCLUSIONS. In patients with elevated IRG-S, we identified characteristic clinical features and 3 additional autoinflammatory diseases: IL-18–mediated PAP and recurrent MAS (IL-18PAP-MAS), NEMO deleted exon 5–autoinflammatory syndrome (NEMO-NDAS), and SAMD9L-associated autoinflammatory disease (SAMD9L-SAAD). The IRG-S expands the diagnostic armamentarium in evaluating USAIDs and points to different pathways regulating IRG expression. TRIAL REGISTRATION. ClinicalTrials.gov NCT02974595. FUNDING. The Intramural Research Program of the NIH, NIAID, NIAMS, and the Clinical Center.

12 July 2018 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
YZYongdong Zhao
Yongdong Zhao
EWEveline Y. Wu
Eveline Y. Wu
MOMelissa S. Oliver
Melissa S. Oliver
ACAshley M. Cooper
Ashley M. Cooper
MBMatthew L. Basiaga
Matthew L. Basiaga
PFPolly J. Ferguson
Polly J. Ferguson

1 August 2018 in Pediatric Clinics of North America
Verified
Journal Article
Closed access
SLSuzanne C. Li
Suzanne C. Li

31 March 2018 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
SRSarah Ringold
Sarah Ringold
PNPeter A. Nigrovic
Peter A. Nigrovic
BFBrian M. Feldman
Brian M. Feldman
GTGeorge A. Tomlinson
George A. Tomlinson
ESEmily von Scheven
Emily von Scheven
YKYukiko Kimura
Yukiko Kimura

18 September 2018 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
CHClaas H. Hinze
Claas H. Hinze
DFDirk Foell
Dirk Foell
AJAnne L. Johnson
Anne L. Johnson
SSSteven J. Spalding
Steven J. Spalding
BGBeth S. Gottlieb
Beth S. Gottlieb
DLDaniel J. Lovell
Daniel J. Lovell
Objective: To determine the relationship between serum levels of S100A8/A9 and S100A12 and the maintenance of clinically inactive disease during anti–tumor necrosis factor (anti‐TNF) therapy and the occurrence of disease flare following withdrawal of anti‐TNF therapy in patients with polyarticular forms of juvenile idiopathic arthritis (JIA).Methods: In this prospective, multicenter study, 137 patients with polyarticular‐course JIA whose disease was clinically inactive while receiving anti‐TNF therapy were enrolled. Patients were observed for an initial 6‐month phase during which anti‐TNF treatment was continued. For those patients who maintained clinically inactive disease over the 6 months, anti‐TNF was withdrawn and they were followed up for 8 months to assess for the occurrence of flare. Serum S100 levels were measured at baseline and at the time of anti‐TNF withdrawal. Spearman's rank correlation test, Mann‐Whitney U test, Kruskal‐Wallis test, receiver operating characteristic (ROC) curve, and Kaplan‐Meier survival analyses were used to assess the relationship between serum S100 levels and maintenance of clinically inactive disease and occurrence of disease flare after anti‐TNF withdrawal.Results: Over the 6‐month initial phase with anti‐TNF therapy, the disease state reverted from clinically inactive to clinically active in 24 (18%) of the 130 evaluable patients with polyarticular‐course JIA; following anti‐TNF withdrawal, 39 (37%) of the 106 evaluable patients experienced a flare. Serum levels of S100A8/A9 and S100A12 were elevated in up to 45% of patients. Results of the ROC analysis revealed that serum S100 levels did not predict maintenance of clinically inactive disease during anti‐TNF therapy nor did they predict disease flare after treatment withdrawal. Elevated levels of S100A8/A9 were not predictive of the occurrence of a disease flare within 30 days, 60 days, 90 days, or 8 months following anti‐TNF withdrawal, and elevated S100A12 levels had a modest predictive ability for determining the risk of flare within 30, 60, and 90 days after treatment withdrawal. Serum S100A12 levels at the time of anti‐TNF withdrawal were inversely correlated with the time to disease flare (r = −0.36).Conclusion: Serum S100 levels did not predict maintenance of clinically inactive disease or occurrence of disease flare in patients with polyarticular‐course JIA, and S100A12 levels were only moderately, and inversely, correlated with the time to disease flare.

10 April 2019 in ACR Open Rheumatology
Verified
Journal Article
Open access
PDF file
EWEveline Y. Wu
Eveline Y. Wu
SLSuzanne C. Li
Suzanne C. Li
KTKathryn S. Torok
Kathryn S. Torok
YVYamini V. Virkud
Yamini V. Virkud
RFRobert C. Fuhlbrigge
Robert C. Fuhlbrigge
TIthe Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry Investigators
the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry Investigators
Objective: Localized scleroderma (LS) is a chronic inflammatory and fibrosing skin disorder. We present baseline data on the juvenile LS (jLS) cohort from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry, a multicenter observational registry of pediatric rheumatologic disorders.Methods: This is a cross‐sectional analysis of children with jLS enrolled in the CARRA Legacy Registry between May 2010 and April 2014. Descriptive statistics were used for demographic, clinical, and laboratory features. Data analysis included two‐sample t test, χ2 test, Fisher's exact test, linear/logistic regression, and analysis of variance.Results: Of 381 children with jLS, 76% were female and 80% Caucasian. Mean onset age was 8.2 years, with 17% having a 2‐year or greater delay to first pediatric rheumatology (PRH) visit. Linear scleroderma was the most common subtype (54%). Antinuclear antibody (ANA) positivity was associated with joint contracture (P = 0.04), muscle atrophy (P = 0.014), and extremity shortening (P = 0.007). Elevated aldolase was associated with joint contracture (P = 0.008) and elevated creatine kinase (CK) with muscle atrophy (P = 0.028) and extremity shortening (P = 0.016). Children with functional limitation (27%) had earlier first PRH visit compared with those without (P = 0.01). Poorer function correlated with muscle atrophy, joint contracture, and extremity shortening (P < 0.001). Methotrexate (97%) and corticosteroids (68%) were the most common medications used.Conclusion: Children with jLS without joint limitation are referred later, highlighting the insidious onset and need for educating referring providers. Poorer function correlated with muscle atrophy, joint contracture, and limb shortening. ANA positivity and elevated CK or aldolase were associated with muscle atrophy, joint contracture, and/or limb shortening, suggesting predictors of muscle involvement.